Literature DB >> 11303496

The MIBG tarot: is it possible to predict the efficacy of beta-blockers in congestive heart failure?

R R Baliga, J Narula, G W Dec.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11303496     DOI： 10.1067/mnc.2001.112837

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN： 1071-3581            Impact factor:   5.952


× No keyword cloud information.
  13 in total

1.  Improvement in left ventricular function in response to carvedilol is accompanied by attenuation of neurohumoral activation in patients with dilated cardiomyopathy.

Authors:  M Fujimura; Y Yasumura; Y Ishida; S Nakatani; K Komamura; M Yamagishi; K Miyatake
Journal:  J Card Fail       Date:  2000-03       Impact factor: 5.712

2.  Improvement of cardiac neuronal function after carvedilol treatment in dilated cardiomyopathy: a 123I-MIBG scintigraphic study.

Authors:  D Agostini; A Belin; M H Amar; Y Darlas; M Hamon; G Grollier; J C Potier; G Bouvard
Journal:  J Nucl Med       Date:  2000-05       Impact factor: 10.057

3.  Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure.

Authors:  P Merlet; H Valette; J L Dubois-Randé; D Moyse; D Duboc; P Dove; M H Bourguignon; C Benvenuti; A M Duval; D Agostini
Journal:  J Nucl Med       Date:  1992-04       Impact factor: 10.057

4.  Iodine-123 metaiodobenzylguanidine myocardial scintigraphy for prediction of response to beta-blocker therapy in patients with dilated cardiomyopathy.

Authors:  M Suwa; Y Otake; A Moriguchi; T Ito; Y Hirota; K Kawamura; I Adachi; I Narabayashi
Journal:  Am Heart J       Date:  1997-03       Impact factor: 4.749

5.  Polymorphisms of the beta(2)-adrenergic receptor determine exercise capacity in patients with heart failure.

Authors:  L E Wagoner; L L Craft; B Singh; D P Suresh; P W Zengel; N McGuire; W T Abraham; T C Chenier; G W Dorn; S B Liggett
Journal:  Circ Res       Date:  2000-04-28       Impact factor: 17.367

Review 6.  Iodine 123-labeled metaiodobenzylguanidine imaging in heart disease.

Authors:  P Merlet; H Valette; J L Dubois-Randé; K Mardon; F Pouillart; M L Bourachot; A Castaigne; A Syrota
Journal:  J Nucl Cardiol       Date:  1994 Mar-Apr       Impact factor: 5.952

7.  Quantitative analysis of 123I-meta-iodobenzylguanidine (MIBG) uptake in hypertrophic cardiomyopathy.

Authors:  K Nakajima; H Bunko; J Taki; M Shimizu; A Muramori; K Hisada
Journal:  Am Heart J       Date:  1990-06       Impact factor: 4.749

8.  Abnormal I-123 metaiodobenzylguanidine myocardial washout and distribution may reflect myocardial adrenergic derangement in patients with congestive cardiomyopathy.

Authors:  E B Henderson; J K Kahn; J R Corbett; D E Jansen; J J Pippin; P Kulkarni; V Ugolini; M S Akers; C Hansen; L M Buja
Journal:  Circulation       Date:  1988-11       Impact factor: 29.690

9.  The Ile164 beta2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure.

Authors:  S B Liggett; L E Wagoner; L L Craft; R W Hornung; B D Hoit; T C McIntosh; R A Walsh
Journal:  J Clin Invest       Date:  1998-10-15       Impact factor: 14.808

10.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.

Authors:  M Packer; M R Bristow; J N Cohn; W S Colucci; M B Fowler; E M Gilbert; N H Shusterman
Journal:  N Engl J Med       Date:  1996-05-23       Impact factor: 91.245
View more
  1 in total

1.  Use of 123I-MIBG scintigraphy to assess the impact of carvedilol on cardiac adrenergic neuronal function in childhood dilated cardiomyopathy.

Authors:  Christophe Maunoury; Philippe Acar; Daniel Sidi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-09-23       Impact factor: 9.236
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.